Evidence map›Paper›PMID 32621283›Full record

ArticleTissue engineering and regenerative medicine2020

Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model.

Xianyao Wang, Huizhen Wang, Junhou Lu, Zhanhui Feng, Zhongshan Liu, Hailiang Song, Heng Wang, Yanhua Zhou, Jianwei Xu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering and regenerative medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xianyao WangNational Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique/Center for Tissue Engineering and Stem Cell Research/Guizhou Province Key Laboratory of Regenerative Medicine, Guizhou Medical University, Beijing Road 9, Guiyang, 550004, Guizhou Province, China.
Huizhen WangDepartment of Stomatology, Nanyang Medical College, Nanyang, 473000, China.
Junhou LuDepartment of Cell Biology, Medical College of Soochow University, Suzhou, 215123, China.
Zhanhui FengNeurological Department, Affiliated Hospital of Guizhou Medical University, Guiyang, 550025, China.
Zhongshan LiuDepartment of Burn and Plastic Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550025, China.
Hailiang SongDepartment of General Surgery, Dalang Hospital, Dongguan, 523000, China.
Heng WangDepartment of Pharmacology, Qiannan Medical College for Nationalities, Duyun, 558000, China.
Yanhua ZhouNational Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique/Center for Tissue Engineering and Stem Cell Research/Guizhou Province Key Laboratory of Regenerative Medicine, Guizhou Medical University, Beijing Road 9, Guiyang, 550004, Guizhou Province, China. 36088035@qq.com.
Jianwei XuNational Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique/Center for Tissue Engineering and Stem Cell Research/Guizhou Province Key Laboratory of Regenerative Medicine, Guizhou Medical University, Beijing Road 9, Guiyang, 550004, Guizhou Province, China. 363912577@qq.com.ORCID 0000-0002-1742-2045
Guiyang Medical University · CNNanyang Medical College · CNSoochow University · CN

Funding

Foundation of Guizhou Provincial Department of Science and Technology [2017] 2873Foundation of Guizhou Provincial Department of Science and Technology [2017] 5718Guizhou Province Science and Technology supporting Plan [2018]2757Science and Technology project of Guiyang City ZKHT [2017]-5-10The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT31048
6 · The paper itself

Abstract

backgroundMesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited.

methodsBone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluated in vivo using immunohistochemical analysis.

resultsEPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl

conclusionEPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.

Indexed as

ErythropoietinMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsFibrosisLiver CirrhosisMiceErythropoietinAnti-fibrosis efficacyBM-MSCsErythropoietinLiver fibrosisMigration

Identifiers

PMID32621283
PMCPMC7333789
OpenAlexW3039643168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.